Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study backs gene therapy for heart failure:

This article was originally published in Clinica

Executive Summary

Collateral Therapeutics' angiogenesis-promoting gene has shown promise as a non-surgical treatment for heart failure, according to results from a placebo-controlled animal study in the March issue of Cardiac and Vascular Regeneration. Intracoronary delivery of the company's human gene fibroblast growth factor-4 (FGF-4) increased heart function and reduced the size of dilated hearts over the three-week study period. The San Diego, California-based company has licensed the gene exclusively from New York University. Collateral is also using the FGF-4 gene to develop a treatment for coronary artery disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel